Teaming Up with Zillion Fine Chemicals to Grow CDMO Business

TAIPEI, Taiwan, March 07, 2025 — Amaran Biotechnology Inc., a subsidiary of OBI Pharma specializing in CDMO services for next-generation pharmaceuticals, today announced the signing of a Memorandum of Understanding (MOU) with Nippon Fine Chemical Co., Ltd., and its Taiwanese subsidiary, Zillion Fine Chemicals International Co., Ltd. The goal is to strengthen their collaboration in CDMO manufacturing for nanoparticle-based drugs and to expand their presence in the CDMO markets of Taiwan, Japan, and other countries.

Capitalizing on Synergies to Advance CDMO Business

Amaran Biotech has Taiwan’s first fully automated robotic aseptic filling line, which provides high-quality, low-waste filling solutions for valuable pharmaceuticals. Nippon Fine Chemical, a Japanese company with a century of history, has specialized in phospholipids technology for over 40 years, with extensive R&D expertise. Their innovative Presome™ series products are used as drug carriers to improve drug targeting and stability, reduce toxicity, and enable sustained release.

Through this partnership, Amaran Biotech will leverage its unique aseptic filling line and CDMO services to support Nippon Fine Chemical’s production of nanoparticle-based drugs, including liposomes and lipid nanoparticles (LNPs). The services will include sterile filtration, aseptic filling, packaging, storage, and quality management. The collaboration also includes Zillion Fine Chemicals’ CDMO operations in Taiwan, with the three companies collaborating to leverage their respective strengths and enhance the technology and services in the CDMO markets of Taiwan, Japan, and other regions.

Industry Leaders Discuss Collaboration Prospects

Dr. Tessie Che, Chairperson and General Manager of Amaran Biotech, commented: “Amaran continues to operate under its motto of “Work Locally. Think and Act Globally”. Ryan Lo, Vice President of Corporate Strategy, Business Development & Regulatory Affairs, emphasized that “Amaran’s industry-leading aseptic filling line and extensive experience in pharmaceutical production have gained Nippon Fine Chemical’s confidence. This collaboration offers a more complete solution for nanoparticle-based drug CDMO and aims to generate synergistic business opportunities that increase the value of our efforts.” Masaki Matsumoto, Senior General Manager of Nippon Fine Chemical, stated: “The nanoparticle-based drug market has significant growth potential. We believe this partnership will greatly boost our CDMO business development in Japan, Taiwan, and the global market.”

About Amaran Biotech
Amaran Biotech is a CDMO specializing in drug process development, analytical services, and cGMP manufacturing of high-value biopharmaceuticals. Amaran Biotech’s advanced manufacturing facility is located in the Hsinchu Biomedical Science Park and has held PIC/S GMP certification from the TFDA since 2017. The company has also been audited and fully qualified by regulatory agencies and third-party auditors from the USA and the EU. In 2020, Amaran Biotech strengthened its collaboration with OBI Pharma Inc. through a stock-for-stock exchange, officially becoming a subsidiary of OBI Pharma. In 2024, its Building C was awarded Green Building Certification by Taiwan’s Ministry of the Interior. Dr. Tessie Che, Chairperson and General Manager of Amaran Biotech, has vast experience in the global pharmaceutical and biotech industries, having successfully led the registration and commercialization of the antibiotic drug DIFICID® (Fidaxomicin) in the U.S., Canada, and Europe. For more information, visit

About Nippon Fine Chemical and Zillion Fine Chemicals
Founded in 1918, Nippon Fine Chemical is a leading company in phospholipids technology in Japan, with over 40 years of experience. Its Presome™ series products are widely used to improve the performance of drug carriers. Zillion Fine Chemicals, its Taiwan subsidiary, concentrates on liposome technology, offering CRO and CDMO services. For more information, visit &

Media Contact: Doreen Lin

“`